Edgewood Oncology, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Edgewood Oncology, Inc. - overview
Location
Brookline, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, Edgewood Oncology, Inc. operates as a biotechnology company that engages in the development of medication for individuals with solid tumors. In March 2024, the firm raised USD 20 million in series A funding led by investor Alta Partners. The firm as of March 2024, is led by its CEO, David N.
Cook, and CMO, Zung Thai. The company engages in the development of treatments for patients with hematologic malignancies and genetically-defined solid tumors. Edgewood’s flagship product, BTX-A51, is a novel small-molecule multi-kinase inhibitor. BTX-A51 targets master regulators of cancer, including CK1α, CDK7, and CDK9, to activate programmed cell death, demonstrating promising clinical activity with a favorable safety profile.
This mechanism of action holds promise in hematologic malignancies and genetically-defined solid tumors, such as GATA3-mutant breast cancer and Liposarcoma. The company plans to utilize the March 2024 funding to progress BTX-A51 in individuals suffering from genetically-defined solid tumors and hematologic malignancies.
Current Investors
Alta Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.edgewoodoncology.com/
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.